Tempus AI Inc. has announced the introduction of xM for treatment response monitoring $(TRM.AU)$, a liquid biopsy assay designed to detect molecular response to immune-checkpoint inhibitor $(ICI.AU)$ therapy in advanced solid tumors. This new assay is part of Tempus' expanding portfolio aimed at monitoring molecular response and minimal residual disease $(MRD.AU)$. Currently available for research use only, clinical availability is anticipated later this year. The xM for TRM assay tracks changes in circulating tumor DNA (ctDNA) dynamics over time, enabling early assessment of molecular response in patients undergoing ICI treatments. Tempus is set to present new data on xM for TRM at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, emphasizing the assay's potential to aid clinicians in monitoring treatment response and refining therapeutic strategies for patients with advanced cancers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.